Aiolos Bio secures $245M Series A to develop breakthrough asthma treatment
TL;DR Summary
Aiolos Bio, founded by former Genentech executives, has raised $245 million in a Series A funding round to advance an asthma drug licensed from China. The startup plans to initiate a Phase II asthma study next year for its anti-TSLP antibody, which is its sole drug candidate. Aiolos Bio's CEO, Khurem Farooq, previously led Gyroscope Therapeutics, which was acquired by Novartis in December 2021.
Topics:business#aiolos-bio#asthma-drug#biotechhealthcare#genentech-vets#series-a-funding#tslp-antibody
- Aiolos Bio launches with $245M Series A, chasing one of asthma's hottest targets Endpoints News
- Startup launches with $245 million for twice yearly asthma treatment STAT
- Aiolos Bio launches with $245M to advance severe asthma med FierceBiotech
- Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody Business Wire
- Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal STAT
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
0 min
vs 1 min read
Condensed
56%
144 → 64 words
Want the full story? Read the original article
Read on Endpoints News